Optimal Timing and Sequence of Immunotherapy When Combined with Stereotactic Radiosurgery in the Treatment of Brain Metastases
Checkpoint immunotherapy (CIT) is an emerging and exciting treatment modality in the treatment of cancer. Much excitement exists in the potential of CIT to revolutionize the treatment and prognosis of brain metastases. The combination of stereotactic radiosurgery (SRS) and CIT has been further studied and showed promise over treatment with either modalities alone. However, several questions arise, particularly the timing at which SRS and CIT are administered relative to each other. This article reviews the current literature and attempts to offer a potential answer to this question.